Accumulation of nonphosphorylated β-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 1, 2007, Pages 338-344

  Björklund, Peyman ^a   Åkerström, Göran ^a   Westin, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; MESSENGER RNA; MYC PROTEIN; WNT PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PARATHYROID ADENOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; SECONDARY HYPERPARATHYROIDISM; UREMIA; WESTERN BLOTTING;

EID: 33846077660     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1197     Document Type: Article

References (36)

1. Marx S 2000 Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 343:1863-1875
2. Arnold A, Shattuck TM, Mallya SM, Krebs LJ, Costa J, Gallagher J, Wild Y, Saucier K 2002 Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 17(Suppl 2):N30-N36
3. Åkerström G, Hellman P 2004 Primary hyperparathyroidism. Curr Opin Oncol 16:1-7
4. Åkerström G, Hellman P, Hessman O, Segersten U, Westin G 2005 Parathyroid glands in calcium regulation and human disease. Ann NY Acad Sci 1040:53-58
5. Hsi ED, Zukerberg LR, Yang WI, Arnold A 1996 Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 81:1736-1739
6. Tominaga Y, Tsuzuki T, Uchida K, Haba T, Otsuka S, Ichimori T, Yamada K, Numano M, Tanaka Y, Takagi H 1999 Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 55:1375-1383
7. Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA 1999 Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 12:412-416
8. Imanishi Y, Hosokawa Y, Yoshimoto K, Schpani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard, F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown, EM, Bronson R, Arnold A 2001 Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1093-1102
9. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A 1991 A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512-515
10. Arnold A 1993 Genetic basis of endocrine disease 5. Molecular genetics of parathyroid gland neoplasia. J Clin Endocrinol Metab 77:1108-1112
11. Polakis P 1999 The oncogenic activation of β-catenin. Curr Opin Genet Dev 9:15-21
12. Lustig B, Behrens J 2003 The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 129:199-221
13. Giles RH, van Es JH, Clevers H 2003 Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653:1-24
14. Moon RT, Kohn AD, DeFerrari GV, Kaykas A 2004 WNT and β-catenin signalling: diseases and therapies. Nat Rev Genet 5:689-701
15. 3-1α-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87: 2967-2972
16. van Noort M, Meeldijk J, van der Zee R, Destree O, Clevers H 2002 Wnt signaling controls the phosphorylation status of β-catenin. J Biol Chem 277: 17901-17905
17. Rowan AJ, Lamlum H, Ilyas M, Wheeler J, Straub J, Papadopoulou A, Bicknell D, Bodmer WF, Tomlinson IPM 2000 APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 97:3352-3357
18. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW 1998 Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512
19. Kremer R, Bolivar I, Goltzman D, Hendy GN 1989 Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 125:935-941
20. Yamaguchi S, Yachiku S, Morikawa M 1997 Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism. J Clin Endocrinol Metab 82:2681-2688
21. Ilyas M, Tomlinson IPM, Rowan A, Pignatelli M, Bodmer WF 1997 β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 94:10330-10334
22. Li Q, Ishikawa TO, Oshima M, Taketo MM 2005 The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis. Cancer Res 65:8622-8627
23. Kielman MF, Rindanpaa M, Gaspar C, van Poppel N, Breukel C, van Leeuwen S, Taketo MM, Roberts S, Smits R, Fodde R 2002 Apc modulates embryonic stem-cell differentiation by controlling the dosage of β-catenin signaling. Nat Genet 32:594-605
24. Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T 2001 Accumulation of β-catenin protein and mutations in exon 3 of β-catenin gene in gastrointestinal carcinoid tumor. Cancer Res 61:6656-6659
25. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW 1997 Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem 272:24735-24738
26. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P 1997 Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275:1790-1792
27. Semba S, Kusumi R, Moriya T, Sasano H 2000 Nuclear accumulation of β-Catenin in human endocrine tumors: association with Ki-67 (MIB-1) proliferative activity. Endocr Pathol 11:243-250
28. Ikeda S, Ishizaki Y, Shimizu Y, Fujimori M, Ojima Y, Okajima M, Sugino K, Asahara T 2002 Immunohistochemistry of cyclin D1 and β-catenin, and mutational analysis of exon 3 of β-catenin gene in parathyroid tumors. Int J Oncol 20:463-466
29. Cryns VL, Yi SM, Tahara H, Gaz RD, Arnold A 1995 Frequent loss of chromosome arm 1p DNA in parathyroid tumors. Genes Chromosomes Cancer 13:9-17
30. Sakai Y, Koizumi K, Sugitani I, Nakagawa K, Arai M, Utsunomiya J, Muto T, Fujita R, Kato Y 2002 Familial adenomatous polyposis associated with multiple endocrine neoplasia type 1-related tumors and thyroid carcinoma. Amer J Surg Pathol 26:103-110
31. Gregory MA, Qi Y, Hann SR 2003 Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem 278:51606-51612
32. Cartwright P, McLean C, Sheppard A, Rivett D, Jones K, Dalton S 2005 LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132:885-896
33. Kim JS, Crooks H, Foxworth A, Waldman T 2002 Proof-of-principle: oncogenic β-catenin is a valid molecular target for the development of pharmacological inhibitors. Mol Cancer Ther 1:1355-1359
34. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB 2003 Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9:1291-1300
35. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR, Kahn M 2004 A small molecule inhibitor of β-catenin/CREB-binding protein transcription. Proc Natl Acad Sci USA 101: 12682-12687
36. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, Shivdasani RA 2004 Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex. Cancer Cell 5:91-102